|
|
|
| Clinical Observation of Xingpi Yanger Combined with Meclofenoxate Hydrochloride Capsule in Treating Infantile Enuresis |
| WAN Juan, LIU Jianying, TANG Guangqun |
| Ziyang First People's Hospital, Sichuan Ziyang 641300, China |
|
|
|
|
Abstract Objective: To explore the clinical efficacy of Xingpi Yanger combined with Meclofenoxate Hydrochloride Capsules in the treatment of enuresis in children. Methods: 148 children with enuresis in our hospital from May 2020 to July 2022 were randomly divided into control group (n=74) and investigation group (n=74) according to random number method. The control group was treated with oral meclofenoxate hydrochloride capsules, and the investigation group was treated with oral meclofenoxate hydrochloride capsules + Xingpi Yanger granules for 4 weeks. To evaluate the clinical efficacy of the two groups and compare the TCM symptom score, enuresis times, sleep awakening disorder score, awakening threshold, bladder capacity, urine osmotic pressure and antidiuretic hormone (ADH) levels before and after treatment in the two groups. The recurrence situation was recorded within 3 months-treatment. Results: The overall response rate of investigation group was 85.14%, higher than control group with 64.86%; After treatment, the TCM symptom score, enuresis frequency, sleep awakening disorder score and awakening threshold index of the two groups were decreased, and the investigation group was lower than the control group; Bladder capacity, urine osmolality, and concentration levels of ADH increased in both groups after treatment, and were higher in the investigation group than in the control group, all these differences were statistically significant (P<0.05).After a follow-up of 3 months, the recurrence rate in study group (8.11%) was statistically lower than that in control group (20.27%). Conclusion: Xingpi Yanger combined with meclofenoxate hydrochloride capsules can significantly improve the clinical efficacy of enuresis in children and reduce the recurrence rate, which is worthy of clinical promotion.
|
|
|
|
|
|
[1] 张亚同,任献青,刘华,等.基于体质特点从"膀胱不约"探讨小儿遗尿的发病与防治[J].中国中医基础医学杂志,2023,29(2):336-338.
[2] 孙香娟,肖祥,吴宣諭,等.小儿遗尿症指南和专家共识质量评价[J].中国全科医学,2023,26(2):134-141.
[3] 李磊,王奥奥,王紫艳,等.醒脾养儿颗粒对正常大鼠排尿功能的影响[J].中国比较医学杂志,2023,33(4):69-75.
[4] 汪受传.中医儿科学[M].第2版.北京:中国中医药出版社,2007.171-173.
[5] 胡思源.遗尿症中药临床试验设计与评价技术指南[J].药物评价研究,2023,46(2):276-282.
[6] 国家中医药管理局.中医病证诊断疗效标准[M].南京大学出版社,1994.
[7] Saffari M,Gholamrezaei A,Saneian H,et al.Linguistic validation of the sleep disturbance scale for children (SDSC) in Iranian children with Persian language[J].Sleep Med,2014,15(8):998-1001.
[8] Beimers W,Braun M,Schwinefus K,et al.A suppressor of dioxygenase inhibition in a yeast model of SDH deficiency[J].Endocr Relat Cancer,2022,29(6):345-358.
[9] 吴闽,杨青.中药治疗小儿遗尿症的系统评价和Meta分析[J].光明中医,2023,38(19):3697-3702.
[10] 吴杰,樊慧苏,林建军,等.缩泉胶囊、醒脾养儿颗粒联合艾灸治疗小儿遗尿症脾肾两虚证临床研究[J].新中医,2021,53(18):89-94.
[11] Douglas A,Baborie A.Inappropriate antidiuretic hormone secretion in amyotrophic lateral sclerosis[J].Clin Neuropathol,2020,39(6):275-281. |
|
|
|
2024, Vol. 30 
